1737-43-5

Basic information

• Product Name: N1-Ethyl-4-fluorobenzene-1,2-diaMine
• Synonyms: N1-Ethyl-4-fluorobenzene-1,2-diaMine;1-N-Ethyl-4-fluorobenzene-1,2-diaMine
• CAS NO: 1737-43-5
• Molecular Formula: C₈H₁₁FN₂
• Molecular Weight: 154.1847432
• Mol File: 1737-43-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 263.9±30.0 °C(Predicted)
• Appearance: /
• Density: 1.169±0.06 g/cm3(Predicted)
• PKA: 5.36±0.11(Predicted)
• CAS DataBase Reference: N1-Ethyl-4-fluorobenzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N1-Ethyl-4-fluorobenzene-1,2-diaMine(1737-43-5)
• EPA Substance Registry System: N1-Ethyl-4-fluorobenzene-1,2-diaMine(1737-43-5)

Safety Data

• Hazardous Substances Data: 1737-43-5(Hazardous Substances Data)

Usage

General Description

N1-Ethyl-4-fluorobenzene-1,2-diaMine, also known as 4-fluoro-N-ethyl-o-phenyleneN1-ethylamine, is a chemical compound with the molecular formula C8H11FN. It is a substituted aniline derivative with a fluorine atom at the 4-position and an ethyl group at the nitrogen atom. N1-Ethyl-4-fluorobenzene-1,2-diaMine is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It may also have potential applications in organic synthesis and materials science. The presence of the fluorine atom and the ethyl group makes it a versatile building block for the preparation of more complex molecules with diverse biological and chemical properties. However, it should be handled and used with caution due to its potential hazards and safety considerations.

Upstream product

• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 774-22-1 4-Fluor-2-nitro-N-ethyl-anilin 

Downstream Products

• 334829-55-9 1-ethyl-5-fluoro-1,3-dihydro-2H-benzimidazol-2-one 

Relevant articles and documents

2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling

Leishmaniasis is a major infectious disease with hundreds of thousands of new cases and over 20,000 deaths each year. The current drugs to treat this life-threatening infection have several drawbacks such as toxicity and long treatment regimens. A library of 1.8 million compounds, from which the hits reported here are publicly available, was screened against Leishmania infantum as part of an optimization program; a compound was found with a 2-aminobenzimidazole functionality presenting moderate potency, low metabolic stability and high lipophilicity. Several rounds of synthesis were performed to incorporate chemical groups capable of reducing lipophilicity and clearance, leading to the identification of compounds that are active against different parasite strains and have improved in vitro proper-ties. As a result of this optimization program, a group of compounds was further tested in anticipation of in vivo evaluation. In vivo tests were carried out with compounds 29 (L. infantum IC50: 4.1 μM) and 39 (L. infantum IC50: 0.5 μM) in an acute L. infantum VL mouse model, which showed problems of poor exposure and lack of efficacy, despite the good in vitro potency.